I’m not familiar with the protocol.
Is it utterly dissociated from the company ? If there was no great benefit being observed full stop then its irrelevant which subject receives the placebo or which receives the application. Would progress be revealed in even the slightest manner to the company?
I’m genuinely curious as I’m placing a lot of faith in the outcome of these trials and we all know that faith can be tested !
Are these protocols “ policed “ as heavily as the rest of the ASX ( cue laughter ) ?
Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-47
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.005(1.37%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 36.0¢ | $391.8K | 1.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 160000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 11013 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
